Focus on sibutramine: A new anorectic agent for the treatment of obesity

Carla A. Luque, Jose A. Rey, Antonio Fernandez

Research output: Contribution to journalReview article

9 Scopus citations

Abstract

Sibutramine HCl is a new anorectic agent given approvable status by the FDA. It is a potent serotonin and norepinephrine reuptake inhibitor, which reportedly is responsible for the enhancement of satiety and stimulation of brown adipose tissue thermogenesis. Clinical trials have indicated that sibutramine is safe and effective, producing a dose-dependent response in the induction and maintenance of weight loss. In comparison with dexfenfluramine, sibutramine has shown similar efficacy over a 12-week period without any associated pulmonary hypertension. Adverse effects commonly associated with sibutramine include dry mouth, constipation, and insomnia. Effective doses range from 5 to 20 mg per day. Sibutramine appears to be an effective pharmacotherapeutic option for obese individuals in whom diet and behavior modifications alone have not achieved the desired outcome.

Original languageEnglish (US)
Pages (from-to)1025-1039
Number of pages15
JournalFormulary
Volume32
Issue number10
StatePublished - Oct 1 1997

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Focus on sibutramine: A new anorectic agent for the treatment of obesity'. Together they form a unique fingerprint.

  • Cite this

    Luque, C. A., Rey, J. A., & Fernandez, A. (1997). Focus on sibutramine: A new anorectic agent for the treatment of obesity. Formulary, 32(10), 1025-1039.